glutathione jp monograph Qualitative and quantitative analysis of

61 One of the most well-known studies of TPE, the double-blind placebo-controlled AD management by albumin replacement (AMBAR) trial, hypothesized that withdrawing plasma might flush A plaque from the brain into the plasma where it could be removed, thereby reducing AD signs and symptoms

Research on rat models with induced arthritis documents reduced cartilage degradation and improved limb function scores in BPC-157-treated subjects

There were higher levels in the high-dose group (3035% increase vs 17% increase in the low-dose group)

These compounds remain without approved clinical trial evidence of safety and effectiveness